Clinical Trial

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.
Protocol Amendment History 1 change
notable Trial sites expanded: 168 -> 174 locations 2026-04-29
Trial Details
NCT Number NCT06747949
Lead Sponsor Amgen
Conditions Sjögren's Syndrome
Enrollment 844 participants
Start Date 2025-02-25
Primary Completion 2029-12-11 (estimated)
Study Completion 2029-12-11 (estimated)
Updated on ClinicalTrials.gov 2026-04-28